Angioplasty & Stenting in India
Get Angioplasty & Stenting at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Angioplasty & Stenting in UAE
Angioplasty & Stenting at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Angioplasty and coronary stenting is a minimally invasive, catheter-based procedure used to restore blood flow through narrowed or blocked coronary arteries, achieving procedural success rates exceeding 95% in high-volume cardiac centres. International patients choose India and the UAE for this intervention because both destinations combine internationally accredited hospitals, experienced interventional cardiologists, and significantly lower out-of-pocket costs compared to the United States, United Kingdom, or Western Europe. GAF Healthcare coordinates end-to-end care across leading cardiac institutions in both countries, giving patients access to drug-eluting stent technology, intravascular imaging guidance, and seamless logistical support from first inquiry through post-discharge follow-up.
Hospital Stay: 2–4 days (1 day in ICU/CCU observation post-procedure, followed by 1–3 days on a monitored cardiac ward) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (short-haul flights generally permitted after 5–7 days if the patient is haemodynamically stable and on optimised dual antiplatelet therapy; long-haul intercontinental flights advised after 10–14 days with cardiologist clearance and compression stocking use) • Success Rate: 95–98% procedural success rate for elective percutaneous coronary intervention (PCI); major adverse cardiovascular event (MACE) rates at 1 year below 5% with modern drug-eluting stents
What Is It?
Coronary artery disease (CAD) develops when atherosclerotic plaques — composed of lipid cores, inflammatory cells, fibrous caps, and calcium deposits — accumulate within the intimal layer of the epicardial coronary arteries. Progressive luminal narrowing (stenosis) restricts myocardial perfusion, producing stable angina pectoris at exertion thresholds proportional to the degree of ischaemia. When a vulnerable plaque ruptures or erodes, acute platelet aggregation and thrombus formation can precipitate an acute coronary syndrome (ACS), encompassing unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or the most time-critical emergency, ST-elevation myocardial infarction (STEMI). Left untreated, sustained ischaemia leads to irreversible myocardial necrosis, ventricular remodelling, heart failure, and potentially fatal arrhythmias.
Percutaneous coronary intervention (PCI) — the umbrella term for balloon angioplasty and coronary stenting — is the globally accepted revascularisation standard for most presentations of obstructive CAD. Under fluoroscopic guidance, an interventional cardiologist advances a guide catheter through the radial or femoral artery to the coronary ostium, crosses the culprit lesion with a 0.014-inch guidewire, inflates a semi-compliant balloon (plain old balloon angioplasty, POBA) to compress the plaque, and then deploys a metallic stent to scaffold the vessel and prevent elastic recoil. Contemporary drug-eluting stents (DES) — third-generation devices coated with antiproliferative agents such as everolimus, zotarolimus, or sirolimus on biodegradable polymer platforms — release drug locally to inhibit neointimal hyperplasia, reducing in-stent restenosis rates to below 5% at one year.
The standard of care for patient selection is evidence-based risk stratification using validated tools: the SYNTAX Score II for multivessel disease (guiding the PCI-versus-CABG decision), the GRACE score for ACS mortality risk, the TIMI risk score, and the EuroSCORE II for surgical risk. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) measurements are used to confirm the haemodynamic significance of intermediate stenoses (40–70%) before committing to stent implantation. Intravascular imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) is increasingly standard to optimise stent sizing, confirm full apposition, and rule out edge dissection — directly reducing the risk of stent thrombosis and target lesion failure.
Candidates
• ELIGIBLE PATIENTS — STABLE CAD:
- Symptomatic stable angina refractory to optimal medical therapy (beta-blockers, calcium channel blockers, long-acting nitrates) with objective evidence of myocardial ischaemia on non-invasive stress testing (exercise ECG, stress echocardiography, nuclear myocardial perfusion imaging [MPI/SPECT], or cardiac MRI perfusion)
- Single-vessel or two-vessel CAD with a SYNTAX Score ≤22 where anatomy is suitable for PCI (Class I, ESC/ACC/AHA guidelines)
- Significant left main coronary artery (LMCA) disease with a SYNTAX Score ≤22 and a Heart Team consensus favouring PCI over CABG
• ELIGIBLE PATIENTS — ACUTE CORONARY SYNDROME:
- STEMI within 12 hours of symptom onset: primary PCI (pPCI) is the preferred reperfusion strategy (door-to-balloon time target <90 minutes)
- High-risk NSTEMI/unstable angina: early invasive strategy (coronary angiography within 24 hours) per GRACE score >140 or positive troponin
- Cardiogenic shock complicating MI: emergent PCI of the culprit vessel
• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:
- 12-lead ECG and continuous cardiac monitoring
- High-sensitivity troponin I or T (serial measurements at 0, 1, and 3 hours for ACS rule-in/rule-out)
- Transthoracic echocardiogram (2D/3D Echo with Doppler): to assess left ventricular ejection fraction (LVEF), regional wall motion abnormalities, valvular function, and pericardial effusion
- Coronary CT angiography (CCTA) with CT-FFR (HeartFlow analysis): increasingly used for non-invasive anatomical and functional assessment of stable CAD before deciding on invasive catheterisation
- Renal function panel (eGFR, serum creatinine): mandatory before contrast administration; patients with eGFR <30 mL/min require pre-hydration and minimised contrast volume
- Full blood count, coagulation profile (INR, aPTT), liver function tests, and HbA1c
- Chest X-ray (PA view)
- Carotid Doppler ultrasound if peripheral vascular disease is suspected
• CONTRAINDICATIONS:
- Absolute: patient refusal or inability to comply with dual antiplatelet therapy (DAPT) for 6–12 months; active life-threatening bleeding; no arterial access route available
- Relative: diffuse multivessel CAD with high SYNTAX Score (>33) where CABG provides superior long-term survival benefit (Heart Team decision required); severe uncorrected contrast allergy not manageable with premedication; severely impaired renal function without dialysis backup; severe uncorrected coagulopathy
- Anatomical: chronic total occlusion (CTO) with unfavourable anatomy, extremely tortuous or heavily calcified vessels (though rotational atherectomy or laser atherectomy can address calcification in experienced centres)
Procedure
STANDARD PCI — BALLOON ANGIOPLASTY AND DRUG-ELUTING STENTING:
The foundational approach involves radial artery access (preferred over femoral for its lower bleeding risk and faster ambulation — the TR Band radial compression protocol), guide catheter engagement, lesion crossing with a 0.014-inch coronary guidewire, pre-dilation with a semi-compliant balloon, and deployment of a third-generation drug-eluting stent (e.g., Absorb BVS successor platforms, Orsiro biodegradable polymer sirolimus stent, Resolute Onyx zotarolimus stent, or Abbott Xience everolimus stent). Post-dilation with a non-compliant balloon at high pressure (16–20 atm) is performed to ensure full stent expansion.
ADVANCED AND COMPLEX PCI TECHNIQUES:
• Intravascular Imaging-Guided PCI (IVUS/OCT): Optical coherence tomography (OCT) provides near-histological resolution (10–20 µm) of plaque morphology, stent strut apposition, and edge dissections. IVUS is superior for ostial left main lesions. Multiple randomised trials (ILUMIEN IV, ULTIMATE) confirm imaging guidance reduces target vessel failure by 25–30% versus angiography-alone guidance.
• Physiological Assessment (FFR/iFR/RFR): A pressure wire is advanced distal to the stenosis; FFR ≤0.80 or iFR ≤0.89 confirms haemodynamic significance. Deferring PCI for FFR >0.80 lesions is safe and avoids unnecessary stenting (DEFER, FAME, FAME 2 trial data).
• Rotational Atherectomy (Rota-ablation): A diamond-tipped burr rotating at 140,000–180,000 rpm ablates heavily calcified plaques that cannot be adequately pre-dilated, enabling stent delivery and full expansion. Used in approximately 5–8% of complex PCI cases.
• Orbital Atherectomy: The Diamondback 360° system uses an elliptical diamond-coated crown to sand down calcium on both sides of the vessel with a single-pass technique.
• Laser Atherectomy (Excimer Laser Coronary Angioplasty, ELCA): Used for in-stent restenosis, uncrossable lesions, and thrombus-containing lesions.
• Chronic Total Occlusion (CTO) PCI: A subspecialty technique using antegrade and retrograde approaches (retrograde via collateral channels), wire escalation algorithms (e.g., Hybrid Algorithm), and specialised CTO guidewires (Confianza Pro 12, Gaia series). Success rates exceed 85–90% in dedicated CTO programmes.
• Bifurcation PCI: Techniques range from the provisional single-stent approach (preferred) to dedicated two-stent strategies: Culotte, Mini-Crush, Double-Kissing (DK) Crush — the latter proven superior in left main bifurcation disease (DKCRUSH-V trial).
• Multivessel PCI with Haemodynamic Support: In patients with severely reduced LVEF (<30%), complex multivessel disease, or cardiogenic shock, percutaneous left ventricular assist devices (Impella CP or Impella 5.5) or intra-aortic balloon pump (IABP) provide circulatory support during high-risk PCI.
• Bioresorbable Vascular Scaffolds (BVS) and Drug-Coated Balloons (DCB): DCBs (paclitaxel or sirolimus-coated) are particularly useful for in-stent restenosis and small vessels where permanent metal implantation is undesirable.
• Transcatheter Heart Valve Procedures (Structural): High-volume cardiac centres in India and the UAE also perform TAVI/TAVR for severe aortic stenosis and MitraClip for mitral regurgitation, providing a full structural heart programme for patients with combined pathology.
MEDICAL THERAPY (MANDATORY ADJUNCT TO PCI):
• Antiplatelet: Aspirin 75–100 mg lifelong PLUS a P2Y12 inhibitor (ticagrelor 90 mg BD or prasugrel 10 mg OD preferred over clopidogrel for ACS; clopidogrel acceptable for stable CAD or high bleeding risk) for 6–12 months DAPT
• Anticoagulation during procedure: Unfractionated heparin (UFH) titrated to ACT 250–300 seconds; bivalirudin (Angiomax) as an alternative in STEMI or HIT
• High-intensity statin therapy: Rosuvastatin 20–40 mg or atorvastatin 40–80 mg initiated immediately
• ACE inhibitor or ARB: For LVEF <40% or hypertension
• Beta-blocker: For post-MI LV dysfunction or ongoing ischaemia
• SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists for patients with concomitant type 2 diabetes and established cardiovascular disease (proven cardiovascular mortality reduction in EMPA-REG OUTCOME and LEADER trials)
Cost of Angioplasty & Stenting: India vs. UAE
The cost of angioplasty and coronary stenting varies significantly depending on the destination country, the complexity of the coronary anatomy (single-vessel versus multivessel PCI), the type of stent selected (bare-metal versus drug-eluting; domestic versus imported brand), the need for adjunctive technologies (IVUS, OCT, rotational atherectomy), and the tier of hospital chosen. India offers among the lowest costs globally for high-quality PCI without compromising on outcomes — major cardiac centres in Mumbai, Chennai, Delhi, and Hyderabad perform thousands of PCI procedures annually with outcomes benchmarked against international registries. The UAE — particularly Dubai and Abu Dhabi — offers premium-tier cardiac care in ultra-modern JCI-accredited facilities, shorter waiting times, and a location accessible within a 4-hour flight radius from much of the Middle East, Eastern Europe, and East Africa, at costs 40–60% below those in the United Kingdom or United States. Both destinations provide third-generation drug-eluting stents, intravascular imaging capability, and 24/7 primary PCI programmes.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $3,000 – $7,000 | ~62% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $8,000 – $18,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL AND REMOTE CONSULTATION (2–4 weeks before travel):
• Patient shares medical records, recent ECG, echocardiogram, stress test reports, and coronary angiography images (if available) with GAF Healthcare's medical team
• A GAF-affiliated senior interventional cardiologist reviews records and provides a written Second Opinion with a personalised treatment plan, estimated cost, and hospital recommendation
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry visa coordination
• Pre-procedure checklist dispatched: medications to continue or withhold (metformin stopped 48 hours before contrast, anticoagulants bridged per protocol), nil-by-mouth instructions, allergy declaration
PHASE 2 — ARRIVAL AND PRE-PROCEDURE WORKUP (Day 1):
• GAF airport representative meets patient and attendant; private transfer to hospital
• Hospital admission and allocation of private room
• Cardiology consultant review and clinical examination
• Same-day diagnostics: 12-lead ECG, 2D echocardiogram, blood panel (troponin, renal function, CBC, coagulation, HbA1c), chest X-ray
• Coronary CT angiography with CT-FFR if coronary anatomy not previously defined by invasive angiogram
• Anaesthesia review (PCI is performed under local anaesthesia with conscious sedation; general anaesthesia reserved for haemodynamically unstable patients or complex CTO cases)
• Patient and attendant briefed on procedure, risks, and consent obtained
• Radial artery Allen's test performed to confirm dual-hand circulation before transradial access
• Pre-procedure DAPT loading: ticagrelor 180 mg or clopidogrel 600 mg; aspirin 300 mg
PHASE 3 — THE PROCEDURE (Day 2, Duration: 45 minutes to 3 hours depending on complexity):
• Patient transferred to the cardiac catheterisation laboratory (Cath Lab), positioned on the angiography table
• Local anaesthesia and radial artery sheath insertion (6F or 7F)
• Diagnostic coronary angiography performed first to confirm anatomy if not previously done
• Heparin administered IV (70–100 units/kg); ACT monitored every 30 minutes
• Guide catheter engaged at coronary ostium; target lesion crossed with 0.014-inch guidewire
• FFR/iFR measurement performed if stenosis severity is ambiguous
• OCT or IVUS run for lesion assessment and stent sizing
• Pre-dilation balloon inflated; stent deployed under fluoroscopy with optimal positioning
• Post-dilation with non-compliant balloon; final OCT/IVUS to confirm full expansion and apposition
• Sheath removed; radial TR Band haemostasis applied
• Patient transferred to Coronary Care Unit (CCU) for 12–24 hours of telemetry monitoring
PHASE 4 — POST-PROCEDURE HOSPITAL RECOVERY (Days 2–4):
• CCU monitoring: continuous ECG telemetry, hourly blood pressure, oxygen saturation
• Serial ECGs at 6 hours and 24 hours post-procedure
• Post-procedure echocardiogram to assess LVEF and wall motion
• Renal function rechecked at 24 and 48 hours post-contrast
• Radial site inspected for haematoma, pseudoaneurysm, or access site complications
• Cardiorespiratory physiotherapy initiated: deep breathing exercises, graduated ambulation from Day 1 post-procedure
• Medications optimised: DAPT, high-intensity statin, ACE inhibitor/ARB, beta-blocker, SGLT2 inhibitor if indicated
• Patient education: DAPT compliance (never stop without cardiologist advice), red-flag symptoms (recurrent chest pain, breathlessness, access site swelling), dietary and lifestyle modification counselling
• Discharge criteria: haemodynamically stable, no access site complications, renal function stable, oral medications initiated
PHASE 5 — IN-COUNTRY RECOVERY (Days 4–14):
• GAF arranges hotel or serviced apartment near hospital for patient and attendant
• Outpatient review at Day 5–7: wound check, ECG, blood pressure monitoring, medication reconciliation
• Cardiac rehabilitation programme initiated (supervised walking programme, heart rate monitoring)
• Mild activities permitted: walking on flat surfaces, self-care activities
• Restrictions: no driving for 5–7 days (radial access); no heavy lifting >5 kg for 2 weeks; no strenuous exercise for 4 weeks
• Short-haul flight (under 4 hours) cleared at Day 5–7 by cardiologist if LVEF >40% and no complications
• Long-haul intercontinental flight cleared at Day 10–14; graduated ambulation every 2 hours in-flight, compression stockings, adequate hydration advised
PHASE 6 — FOLLOW-UP AFTER RETURN HOME:
• GAF Healthcare provides a comprehensive discharge summary, medication list, and follow-up protocol for the patient's home cardiologist
• Teleconsultation with the treating cardiologist at 1 month, 3 months, and 6 months post-procedure
• Exercise stress test or nuclear MPI recommended at 9–12 months to assess stent patency
• Lifelong aspirin; P2Y12 inhibitor for minimum 6 months (12 months for ACS); never discontinue DAPT without prior cardiology consultation
Risks & Considerations
Angioplasty and coronary stenting is a well-established, low-risk procedure in experienced hands, but patients must be counselled on specific complications to make a fully informed decision. Vascular access site complications — including radial artery spasm, haematoma, pseudoaneurysm, or radial artery occlusion — occur in 1–3% of transradial cases and are generally minor. The most feared acute complication is stent thrombosis: an abrupt occlusion of the stent by thrombus, occurring in <1% of cases acutely and <0.5% per year thereafter; it is catastrophically associated with myocardial infarction and death, and is almost entirely preventable by strict adherence to dual antiplatelet therapy (DAPT). Patients must never self-discontinue clopidogrel, ticagrelor, or prasugrel without explicit cardiologist guidance, particularly within the first 12 months of stent implantation. Contrast-induced nephropathy (CIN) occurs in 1–5% of patients — risk is substantially higher in those with pre-existing chronic kidney disease (eGFR <60 mL/min), diabetes, or myeloma; mitigation strategies include IV pre-hydration with normal saline or sodium bicarbonate, use of iso-osmolar or low-osmolar contrast agents (iohexol, iopamidol), and minimising contrast volume. Coronary artery dissection or perforation are rare (<0.5%) but potentially life-threatening procedural complications requiring emergent pericardiocentesis or covered stent deployment. Radiation exposure from fluoroscopy is minimised by the use of low-dose pulse fluoroscopy protocols and experienced operators. In-stent restenosis — symptomatic re-narrowing within the stent due to neointimal hyperplasia — occurs in 3–7% of drug-eluting stent recipients at 1–2 years, treatable by repeat PCI with a drug-coated balloon or second DES. For patients with multivessel CAD and high SYNTAX scores, the risk of repeat revascularisation is meaningfully higher with PCI than with coronary artery bypass grafting (CABG); the Heart Team decision-making process — involving an interventional cardiologist, cardiac surgeon, and the patient — is essential to ensure the correct revascularisation strategy is chosen for complex disease. Patients travelling internationally should carry a stent implantation card detailing stent brand, size, implantation date, and antiplatelet regimen for presentation to any emergency physician if chest pain recurs during their journey.
Top Hospitals for Angioplasty & Stenting
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Fortis Memorial Research Institute
Gurgaon, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Top Doctors for Angioplasty & Stenting
Internationally trained specialists in Cardiology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Krishna S Iyer
MBBS, MS (Surgery), M.Ch (Cardiothoracic Surgery), Fellowship in Infant Cardiac Surgery
Pediatric Cardiac Surgeon
Fortis Escorts Heart Institute, New Delhi, India
35+ Yearsof experience
Dr. Krishna S Iyer is one of India's most experienced and internationally recognised pediatric cardiac surgeons. As Executive Director of Pediatric and Congenital Heart Surgery at Fortis Escorts Heart Institute in Okhla, New Delhi, he has devoted his career to giving children with congenital heart disease — some of the most complex and delicate patients in all of medicine — the best possible chance at a full life. After his medical training, Dr. Iyer… Read more
Dr. Devi Shetty
MBBS, MS (General Surgery), MCh (Cardiothoracic Surgery), Fellowship in Cardiac Surgery
Cardiac Surgeon
Narayana Health, Bengaluru, India
38+ Yearsof experience
Dr. Devi Prasad Shetty is one of the most respected and widely recognised cardiac surgeons in the world. He is the founder and chairman of Narayana Health, a hospital chain that has redefined what affordable, high-quality cardiac care looks like — not only in India, but globally. Early in his career, Dr. Shetty trained at Guy's Hospital in London, one of the oldest teaching hospitals in Britain. He later served as personal physician to Mother Teresa, an… Read more
Dr. Naresh Trehan
MBBS, MS (General Surgery), Fellowship in Cardiothoracic Surgery
Cardiothoracic Surgeon
Medanta – The Medicity, Gurgaon, India
40+ Yearsof experience
Dr. Naresh Trehan is widely regarded as one of the most accomplished cardiovascular and cardiothoracic surgeons of his generation. With more than four decades of clinical practice spanning India and the United States, he has performed over 48,000 cardiac surgeries and has consistently ranked among the best heart surgeons in Asia. Born and educated in India, Dr. Trehan completed his advanced surgical training at New York University Medical Center, where he… Read more
Dr. Z S Meharwal
MBBS, MS (Surgery), MCh (Cardiothoracic Surgery), MNAMS
Cardiothoracic Surgeon
Fortis Escorts Heart Institute, New Delhi, India
30+ Yearsof experience
Dr. Z S Meharwal is part of the founding team of doctors at Fortis Escorts Heart Institute in Okhla, New Delhi, one of India's most respected cardiac centres. With more than 30 years of experience in cardiac surgery and over 30,000 surgeries to his credit — including many of the most complex heart operations performed in the country — he stands as one of the most accomplished cardiothoracic surgeons of his generation. Dr. Meharwal is a pioneer in many new… Read more
Dr. Ritwick Raj Bhuyan
MBBS, MS (Surgery), M.Ch (Cardiothoracic Surgery), Senior Registrar – CTVS, Visiting Fellowship (Heart Transplant & VAD)
Cardiothoracic Surgeon
Fortis Escorts Heart Institute, New Delhi, India
20+ Yearsof experience
Dr. Ritwick Raj Bhuyan is a Cardiothoracic and Vascular Surgeon with 20 years of working experience in high-volume cardiothoracic centres in India and Australia. Currently serving as Director of Cardio Thoracic Vascular Surgery at Fortis Escorts Heart Institute in Okhla, New Delhi, he has been associated with nearly 15,000 open heart procedures and has performed more than 7,000 open heart surgeries independently — a figure that places him among the most… Read more
Frequently Asked Questions — Angioplasty & Stenting
The total cost of angioplasty and coronary stenting in India typically ranges from USD 3,000 to USD 7,000, depending on the complexity of the procedure (single-vessel versus multivessel PCI), the type of stent used (third-generation drug-eluting stents from brands such as Abbott Xience, Medtronic Resolute Onyx, or Biotronik Orsiro), and whether advanced adjunctive technologies such as intravascular imaging (OCT or IVUS) or rotational atherectomy are required. This cost generally includes catheterisation laboratory fees, stent costs, one to three nights in a private hospital room, standard medications including the initial loading dose of dual antiplatelet therapy, nursing care, and cardiologist fees. In the UAE — specifically Dubai and Abu Dhabi — the same procedure at a JCI-accredited hospital such as Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai, or American Hospital Dubai typically costs between USD 8,000 and USD 18,000, reflecting the higher operational costs, luxury hospital infrastructure, and imported premium stent pricing in that market. India is therefore approximately 50–65% less expensive than the UAE for equivalent clinical outcomes. Both destinations offer procedures performed by senior interventional cardiologists trained at leading international institutions, using the same generation of drug-eluting stents and imaging equipment available in Europe or North America. GAF Healthcare provides itemised cost estimates for each patient based on their specific clinical file before any commitment is made.
For most patients undergoing elective single-vessel or two-vessel PCI via the transradial approach without complications, the treating cardiologist will typically provide fitness-to-fly clearance for short-haul flights (under four hours) as early as five to seven days after the procedure. For long-haul intercontinental flights — for example, from India to the UK, or from the UAE to West Africa or North America — a minimum of ten to fourteen days post-procedure in-country stay is recommended by most interventional cardiologists and is consistent with guidance from the British Cardiovascular Society and the European Society of Cardiology. The primary reasons for this recovery period are: ensuring that the access site (radial or femoral artery) is fully healed and there is no haematoma or pseudoaneurysm; confirming haemodynamic stability and that the left ventricular ejection fraction (LVEF) has not deteriorated; allowing adequate time for the loading doses of dual antiplatelet therapy (DAPT) to achieve full platelet inhibition; and reducing the risk of deep vein thrombosis (DVT) associated with prolonged immobility during air travel. Patients who have undergone complex PCI — including multivessel stenting, CTO intervention, rotational atherectomy, or who had periprocedural complications — may require a longer in-country stay of two to three weeks. During the flight itself, patients are advised to ambulate briefly every one to two hours, maintain adequate hydration, wear graduated compression stockings (15–20 mmHg), and carry a copy of their stent card, discharge summary, and current medication list. GAF Healthcare ensures that every patient receives a written fit-to-fly letter from the treating cardiologist and that travel documentation is prepared prior to hospital discharge.
The procedural success rate of contemporary percutaneous coronary intervention (PCI) — defined as achieving less than 20% residual stenosis with TIMI grade 3 (normal) flow and no in-hospital major adverse cardiovascular events (MACE) — exceeds 95 to 98% in high-volume, experienced cardiac centres in both India and the UAE. For elective single-vessel PCI of a straightforward stenosis, success rates in accredited Indian and UAE centres match those published by the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). At one year following drug-eluting stent implantation, the rate of major adverse cardiovascular events (MACE — comprising cardiac death, recurrent myocardial infarction, or target vessel revascularisation) is below five percent in most contemporary drug-eluting stent trials, including RESOLUTE-III, BIOSTEMI, and TALENT. For primary PCI in STEMI (heart attack), door-to-balloon times below 90 minutes — the international benchmark — are consistently achieved in partner hospitals with 24/7 primary PCI programmes. Long-term stent patency data shows that third-generation biodegradable-polymer drug-eluting stents have in-stent restenosis rates of three to six percent at two years, a dramatic improvement over bare-metal stents (20–30% restenosis) from the earlier era. For complex cases — chronic total occlusions, multivessel disease, left main interventions — success rates and long-term outcomes depend heavily on the operator's experience and the use of intravascular imaging guidance; GAF Healthcare refers patients exclusively to centres with documented high-volume complex PCI programmes and published outcomes data.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully coordinated, concierge-level medical travel service covering every non-clinical aspect of the patient's journey to India or the UAE.
VISA ASSISTANCE — INDIA: GAF Healthcare's case coordinators prepare and guide patients through the Indian e-Medical Visa application, which is available to citizens of over 160 countries. The e-Medical Visa is processed online in 3–5 business days, is valid for 60 days with triple entry, and permits entry through 30 designated international airports including Delhi Indira Gandhi, Mumbai Chhatrapati Shivaji, Chennai, Hyderabad, and Kochi. GAF provides all required supporting documentation: a formal hospital invitation letter on hospital letterhead, a treatment cost estimate, and guidance on the photograph and passport specifications required by the Indian Visa Application Centre.
VISA ASSISTANCE — UAE (DUBAI AND ABU DHABI): Citizens of GCC countries, the European Union, the United States, United Kingdom, Canada, Australia, and approximately 50 additional nationalities receive visa-free entry or visa-on-arrival access to the UAE for 30–90 days — no pre-approval required. For nationalities requiring advance UAE visas, GAF facilitates a UAE Medical Treatment Visa or Tourist Visa application through its UAE partner hospitals, which serve as sponsors. The process typically takes 3–7 business days.
AIRPORT TRANSFERS AND GROUND LOGISTICS: A dedicated GAF Healthcare representative meets the patient and attendant at the arrivals gate of all major partner airports, carrying a personalised name card. Private, air-conditioned vehicle transfers are arranged to the hospital — not shared taxis or public transport. Wheelchair assistance and porter services are pre-arranged where required. Return transfers to the airport at discharge are included in the GAF coordination package.
MEDICAL INTERPRETERS AND TRANSLATORS: GAF Healthcare provides professional medical interpreters fluent in Arabic, Russian, French, Swahili, Uzbek, and other languages upon request. Interpretation is available in-person during consultations, procedures, and discharge briefings, as well as via video call for patients who prefer remote support. All medical documents — consent forms, discharge summaries, prescription records — are translated into the patient's preferred language.
ATTENDANT ACCOMMODATION: GAF Healthcare arranges accommodation for one or two accompanying family members or caregivers within 1–3 kilometres of the treating hospital. Options range from budget-friendly serviced guesthouses to 4-star hotels depending on the patient's preference and budget. In many partner hospitals, attendant stay within the private room is included in the room rate; GAF confirms these details during the pre-admission planning stage.
COMMUNICATION AND 24/7 SUPPORT: A dedicated GAF case manager is assigned to each patient before departure and remains the single point of contact throughout the entire medical journey — from visa paperwork to post-discharge teleconsultation scheduling. A 24/7 emergency helpline is available for any clinical or logistical concern arising during the patient's stay.
Patients Also Explore
Other treatments commonly sought by patients considering Angioplasty & Stenting.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Brain Tumor Surgery
Neurology
Deep Brain Stimulation
Neurology